for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AB Science SA

ABS.PA

Latest Trade

14.26EUR

Change

0.02(+0.14%)

Volume

28,319

Today's Range

14.14

 - 

14.42

52 Week Range

7.92

 - 

21.75

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
14.24
Open
14.16
Volume
28,319
3M AVG Volume
2.93
Today's High
14.42
Today's Low
14.14
52 Week High
21.75
52 Week Low
7.92
Shares Out (MIL)
52.46
Market Cap (MIL)
662.91
Forward P/E
--
Dividend (Yield %)
--

Next Event

Ab Science SA Annual Shareholders Meeting

Latest Developments

More

AB Science FY Net Loss Narrows To EUR 15 Mln

AB Science Secures EUR 6 MLN In Non-Dilutive Financing Guaranteed By French Government

AB Science: New Publication Says Masitinib Has Anti-Vital Activity Against SARS-CoV-2 Virus

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AB Science SA

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

Industry

Biotechnology & Drugs

Contact Info

3 avenue George V

75008

France

+33.1.47200014

http://www.ab-science.com/

Executive Leadership

Alain Moussy

Chairman of the Board, Chief Executive Officer

Denis Gicquel

Deputy Chief Executive Officer

Laurent Guy

Chief Financial Officer

Jean-Pierre Kinet

Director

Patrick Moussy

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
418.77
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-566.28
Return on Equity (TTM)
-63.45

Latest News

Latest News

BRIEF-AB Science: Publication Of New Results With Masitinib

* AB SCIENCE ANNOUNCES THAT NEW RESULTS PUBLISHED IN THE PEER-REVIEWED JOURNAL OF ALZHEIMER'S DISEASE SUPPORT MASITINIB'S POTENTIAL MODE OF ACTION IN ALZHEIMER'S DISEASE

BRIEF-AB Science Postpones AGM To No Later Than September 30

* ANNOUNCES THE POSTPONEMENT OF ITS ANNUAL GENERAL SHAREHOLDERS’ MEETING

BRIEF-AB Science Granted Authorization By ANSM To Initiate Phase 2 Study Evaluating Masitinib In Combination With Isoquercetin For The Treatment Of Covid-19

* AB SCIENCE GRANTED AUTHORIZATION BY ANSM TO INITIATE PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN FOR THE TREATMENT OF COVID-19 Source text for Eikon: Further company coverage:

BRIEF-AB Science Initiates Phase 2 Study Evaluating Masitinib In Combination With Isoquercetin For Treatment Of COVID-19

* REG-AB SCIENCE GRANTED AUTHORIZATION BY ANSM TO INITIATE PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN FOR THE TREATMENT OF COVID-19

BRIEF-AB Science FY Consolidated Net Loss Narrows To EUR 21.7 Mln

* FY CONSOLIDATED NET REVENUE EUR 1.6 MILLION VERSUS EUR 1.7 MILLION YEAR AGO

BRIEF-AB Science Sees Limited COVID-19 Impact On Clinical Development Programme

* REG-LETTER TO AB SCIENCE STAKEHOLDERS ON COVID-19 PANDEMIC IMPACT ON AB SCIENCE CLINICAL STUDIES

BRIEF-AB Science: FDA Clears Masitinib IND In Amyotrophic Lateral Sclerosis

* FDA CLEARS MASITINIB IND IN AMYOTROPHIC LATERAL SCLEROSIS (ALS), ALLOWING U.S. PATIENT ENROLLMENT TO COMMENCE IN PHASE 3 STUDY

BRIEF-AB Science Announces New Fundraising Of 12.3 Million Euros

* REG-AB SCIENCE ANNOUNCES A NEW FUNDRAISING OF EUR 12.3 MILLION

BRIEF-AB Science: 1st Presentation Of Preclinical Results For Compound AB8939

* ANNOUNCED ON WEDNESDAY FIRST PRESENTATION OF PRECLINICAL RESULTS FOR COMPOUND AB8939 IN THE 61ST ASH ANNUAL MEETING ONLINE PROGRAM

BRIEF-AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005

* ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER

BRIEF-AB Science Presents New Preclinical Data For Masitinib In ALS

* ANNOUNCED ON TUESDAY NEW PRECLINICAL DATA FOR MASITINIB IN ALS AT 2019 MUSCULAR DYSTROPHY ASSOCIATION CONFERENCE

BRIEF-AB Science FY Operating Loss Down At 28.4 Million Euros

* FY NET LOSS EUR 27.1 MILLION VERSUS LOSS OF EUR 27.7 MILLION YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up